Jason Eric Evans
Known title: DirectorCIK: 0001670094
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Teladoc Launches AI-Powered Remote Monitoring Tools. Teladoc Health has introduced new AI features that turn smartphone cameras into vital sign monitors and add ambient care tools to its Solo platform. These updates aim to strengthen the company's competitive position in digital health. While the stock has recently dipped more than the broader market, analysts maintain an average price target of $7.59, suggesting potential value relative to current levels.
Transaction History
| SGRY | ▼ Sell | Open Market | 20,400 | $254K | 3/16/2026 | View on chart |
| SGRY | ▼ Sell | Open Market | 11,462 | $158K | 3/6/2026 | View on chart |
| SGRY | ▲ Buy | Grant | 141,743 | $2.0M | 3/5/2026 | View on chart |
| SGRY | ▲ Buy | Grant | 136,363 | $1.9M | 3/5/2026 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 1,016 | — | 12/19/2025 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 1,016 | — | 9/19/2025 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 1,016 | — | 6/20/2025 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 1,016 | — | 3/20/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 84,033 | $2.0M | 3/4/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 29,411 | $700K | 3/4/2025 | View on chart |
| SGRY | ▼ Sell | Open Market | 26,520 | $680K | 2/7/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 111,048 | $0 | 1/31/2025 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 1,016 | — | 12/20/2024 | View on chart |
| SGRY | ▲ Buy | Option Exercise | 16,500 | $190K | 12/12/2024 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 4,065 | — | 9/20/2024 | View on chart |
| SGRY | ▼ Sell | Open Market | 4,840 | $144K | 3/13/2024 | View on chart |
| SGRY | ▼ Sell | Open Market | 1,984 | $58K | 3/11/2024 | View on chart |
| SGRY | ▼ Sell | Open Market | 9,070 | $278K | 3/4/2024 | View on chart |
| SGRY | ▲ Buy | Grant | 56,446 | $1.8M | 2/28/2024 | View on chart |
| SGRY | ▼ Sell | Open Market | 5,780 | $203K | 2/12/2024 | View on chart |
| SGRY | ▼ Sell | Open Market | 5,000 | $167K | 12/19/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 1,892 | $85K | 6/29/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 7,674 | $263K | 3/31/2023 | View on chart |
| SGRY | ▲ Buy | Grant | 20,408 | $0 | 3/24/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 99 | $3K | 3/15/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 12,399 | $386K | 3/14/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 10,300 | $310K | 3/13/2023 | View on chart |
| SGRY | ▲ Buy | Grant | 66,950 | $2.2M | 3/2/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 20,042 | $672K | 2/27/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 5,884 | $199K | 2/13/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 2,042 | $114K | 5/3/2022 | View on chart |
| SGRY | ▼ Sell | Open Market | 11,467 | $630K | 4/1/2022 | View on chart |
| SGRY | ▼ Sell | Open Market | 14,065 | $693K | 3/15/2022 | View on chart |
| SGRY | ▲ Buy | Grant | 37,016 | $2.0M | 3/11/2022 | View on chart |
| SGRY | ▼ Sell | Open Market | 5,061 | $277K | 3/11/2022 | View on chart |
| SGRY | ▼ Sell | Open Market | 14,071 | $735K | 2/28/2022 | View on chart |
| SGRY | ▲ Buy | Grant | 29,732 | $1.2M | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation
Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.